What is Sagent Pharmaceuticals?
Founded in 2006 and headquartered in Schaumburg, Illinois, Sagent Pharmaceuticals operates as a specialized developer and distributor of generic injectable medications. By focusing on high-barrier-to-entry pharmaceutical products, the company has carved out a significant niche in the healthcare sector. Its business model emphasizes the delivery of cost-effective, high-quality therapeutic solutions to hospitals and healthcare providers, effectively bridging the gap between complex manufacturing requirements and the urgent needs of the clinical market. The company's growth strategy is underpinned by a commitment to operational excellence and a robust supply chain, which has allowed it to maintain a competitive edge in the generic injectables market.
How much funding has Sagent Pharmaceuticals raised?
Sagent Pharmaceuticals has raised a total of $162M across 3 funding rounds:
Series A
$30M
Series B
$40M
Stock Offering
$92M
Series A (2009): $30M with participation from Vivo Ventures
Series B (2010): $40M, investors not publicly disclosed
Stock Issuance/Offering (2011): $92M, investors not publicly disclosed
Key Investors in Sagent Pharmaceuticals
Vivo Ventures
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
What's next for Sagent Pharmaceuticals?
With the infusion of $92M, Sagent Pharmaceuticals is well-positioned to accelerate its product pipeline and expand its manufacturing capabilities. The current lifecycle stage, characterized by major enterprise-level funding, suggests a transition toward broader market penetration and potential portfolio diversification. Future strategic initiatives will likely focus on enhancing production efficiencies and navigating the regulatory complexities inherent in the biopharmaceutical industry. As the company continues to scale, investors and industry analysts will be monitoring its ability to maintain margins while navigating the evolving landscape of generic drug pricing and healthcare procurement policies.
See full Sagent Pharmaceuticals company page
